StreetInsider.com News Articles

Prime Drink Group Provides Bi-Weekly MCTO Status Report

Thu, 27 Aug 2026 17:30:00 -0400

MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news releases dated July 30 and August 14, 2026, the Company voluntarily applied for and the Company’s principal regulator, the British Columbia Securities Commission (the “BCSC”) granted a management cease trade order (the “MCTO”) dated July 30, 2026, under National Policy 12-203 Management Cease Trade Orders (“NP 12-203”) and provided the Company with an extension to file its annual financial statements for the year ended March 31, 2026, including the related management’s discussion and analysis,

Prime Drink Group Provides Bi-Weekly MCTO Status Report

Thu, 27 Aug 2026 17:30:00 -0400

Prime Drink Group Provides Bi-Weekly MCTO Status Report

Thu, 27 Aug 2026 17:30:00 -0400

Prime Drink Group Provides Bi-Weekly MCTO Status Report

Thu, 27 Aug 2026 17:30:00 -0400

Prime Drink Group signs LOI with Geloso for beverage brand expansion

Thu, 27 Aug 2026 07:31:49 -0400

Prime Drink Group Corp. (CSE: PRME) has signed a non-binding letter of intent with GefCo, a company within Les Entreprises du Groupe Geloso, to form a strategic partnership for the distribution, marketing, production and development of its Beach Day Every Day (BDED) beverage brand across Canada outside Quebec, the United States and Europe.

Under the proposed structure, Prime and Geloso would each hold a 50% stake in a newly incorporated company, to be managed by Aldo Geloso. Prime would contribute the BDED assets to the new entity, while Geloso would oversee operations and management across the defined territory.

The parties intend to

Prime Drink Group signs LOI with Geloso for beverage brand expansion

Thu, 27 Aug 2026 07:31:49 -0400

The parties intend to

Prime Drink Group Enters Into Strategic Partnership With Groupe Geloso to Accelerate the Expansion of Beach Day Every Day Across the Rest of Canada, the United States and Europe

Thu, 27 Aug 2026 07:30:00 -0400

MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is proud to announce that it has entered into a non-binding letter of intent (the “Partnership LOI”) with 9435-7639 Québec Inc., doing business as GefCo (“GefCo”), a company forming part of Les Entreprises du Groupe Geloso (“Geloso”).

Pursuant to the Partnership LOI, Prime and Geloso will form a strategic partnership for the distribution, marketing, production and development of the Beach Day Every Day (“BDED”) business across the rest of Canada, excluding Quebec, as well as the United States

Prime Drink Group Enters Into Strategic Partnership With Groupe Geloso to Accelerate the Expansion of Beach Day Every Day Across the Rest of Canada, the United States and Europe

Thu, 27 Aug 2026 07:30:00 -0400

Prime Drink Group Enters Into Strategic Partnership With Groupe Geloso to Accelerate the Expansion of Beach Day Every Day Across the Rest of Canada, the United States and Europe

Thu, 27 Aug 2026 07:30:00 -0400

Prime Drink Group Enters Into Strategic Partnership With Groupe Geloso to Accelerate the Expansion of Beach Day Every Day Across the Rest of Canada, the United States and Europe

Thu, 27 Aug 2026 07:30:00 -0400

BMO Capital Starts Prime Medicine (PRME) at Outperform

Wed, 19 Aug 2026 05:34:13 -0400

(Updated - August 19, 2026 5:34 AM EDT)

BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ: PRME) with a Outperform rating, PT $9.00.

The analyst comments "We initiate coverage of Prime Medicine with an Outperform rating and a $9 target price. Prime Editing is a differentiated, next-generation gene-editing platform that supports a broad range of precise edits without introducing double-strand breaks in DNA. Lead programs PM577 in Wilson's Disease and PM647 in AATD are advancing toward initial clinical readouts in 2027, where positive and differentiated profiles could validate their best-in-class and blockbuster potential, de-risk Prime’s in vivo editing platform,

BMO Capital Starts Prime Medicine (PRME) at Outperform

Wed, 19 Aug 2026 05:34:13 -0400

(Updated - August 19, 2026 5:34 AM EDT)

BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ: PRME) with a Outperform rating, PT $9.00.

Prime Drink Group Provides Bi-Weekly MCTO Status Report

Fri, 14 Aug 2026 16:00:00 -0400

MONTREAL, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news release dated July 30, 2026, the Company voluntarily applied for and the Company’s principal regulator, the British Columbia Securities Commission (the “BCSC”) granted a management cease trade order (the “MCTO”) dated July 30, 2026, under National Policy 12-203 Management Cease Trade Orders (“NP 12-203”) and provided the Company with an extension to file its annual financial statements for the year ended March 31, 2026, including the related management’s discussion and analysis, and Chief Executive

Prime Drink Group Provides Bi-Weekly MCTO Status Report

Fri, 14 Aug 2026 16:00:00 -0400

Prime Drink Group Provides Bi-Weekly MCTO Status Report

Fri, 14 Aug 2026 16:00:00 -0400

Prime Drink Group Provides Bi-Weekly MCTO Status Report

Fri, 14 Aug 2026 16:00:00 -0400

Prime Medicine, Inc. (PRME) Tops Q2 EPS by 12c

Thu, 06 Aug 2026 08:33:38 -0400

Prime Medicine, Inc. (NASDAQ: PRME) reported Q2 EPS of ($0.24), $0.12 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $1.15 million.

For earnings history and earnings-related data on Prime Medicine, Inc. (PRME) click here.

Form 10-Q Prime Medicine, Inc. For: Jun 30

Thu, 06 Aug 2026 08:04:00 -0400

si-local-file:///var/storage/secattach/20260806/26879334.html

Form 10-Q Prime Medicine, Inc. For: Jun 30

Thu, 06 Aug 2026 08:04:00 -0400

si-local-file:///var/storage/secattach/20260806/26879334.html

Form 8-K Prime Medicine, Inc. For: Aug 06

Thu, 06 Aug 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26879314.html

Form 8-K Prime Medicine, Inc. For: Aug 06

Thu, 06 Aug 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26879314.html

Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 06 Aug 2026 08:00:00 -0400

-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 --

-- Favorable arbitration resolution with Beam Therapeutics affirms Prime Medicine’s rights to PM647 in Alpha-1 Antitrypsin Deficiency; IND and/or CTA submission expected in 3Q 2026, with initial clinical data in 2027 --

-- FDA grants Regenerative Medicine Advanced Therapy designation to PM359; continued regulatory engagement with the FDA toward a BLA submission for PM359 in 1H 2027 --

Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 06 Aug 2026 08:00:00 -0400

-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 --

-- Favorable arbitration resolution with Beam Therapeutics affirms Prime Medicine’s rights to PM647 in Alpha-1 Antitrypsin Deficiency; IND and/or CTA submission expected in 3Q 2026, with initial clinical data in 2027 --

-- FDA grants Regenerative Medicine Advanced Therapy designation to PM359; continued regulatory engagement with the FDA toward a BLA submission for PM359 in 1H 2027 --

--

Prime Drink Group extends private placement, misses filing deadline

Thu, 30 Jul 2026 17:30:13 -0400

Prime Drink Group Corp. (CSE: PRME) has extended a non-brokered private placement and disclosed that it missed the deadline to file its annual financial statements, according to a press release from the Montreal-based company.

The unit offering, originally announced June 12, 2026, seeks to raise between $1,200,000 and $2,200,000 and is now expected to close on or by September 14, 2026. Each unit is priced at $10,000 and consists of 200,000 common shares at a deemed price of $0.05 per share and 200,000 warrants exercisable at $0.10 per share for one year from issuance. The offering would result in the issuance

Prime Drink Group extends private placement, misses filing deadline

Thu, 30 Jul 2026 17:30:13 -0400

Prime Drink Group Corp. (CSE: PRME) has extended a non-brokered private placement and disclosed that it missed the deadline to file its annual financial statements, according to a press release from the Montreal-based company.

The unit offering, originally announced June 12, 2026, seeks to raise between $1,200,000 and $2,200,000 and is now expected to close on or by September 14, 2026. Each unit is priced at $10,000 and consists of 200,000 common shares at a deemed price of $0.05 per share and 200,000 warrants exercisable at $0.10 per share for one year from issuance. The offering would result in the issuance